Results 81 to 90 of about 162,034 (289)

Antisense oligonucleotides used in this study.

open access: yes, 2013
Antisense oligonucleotides used in this study.
Willem M. H. Hoogaars (430632)   +8 more
core   +1 more source

Metastasis Pattern‐Specific Biomarkers and Therapeutic Targets in Gastric Cancer: From Surgical Specimens to Clinical Translation

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Gastric cancer metastasis should be considered according to its anatomical route, because lymphatic, peritoneal, and hematogenous dissemination involve partly distinct molecular mechanisms. This review summarizes metastasis pattern‐associated and pattern‐specific molecules identified using surgical specimens, evaluates their evidence and translational ...
Mitsuro Kanda
wiley   +1 more source

Antisense oligonucleotides tested in the present study.

open access: yes, 2014
Antisense oligonucleotides tested in the present study.
Steve D. Wilton (190383)   +6 more
core   +1 more source

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

open access: yesAnnals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring   +18 more
wiley   +1 more source

2′-OMe antisense oligonucleotides.

open access: yes, 2015
2′-OMe antisense oligonucleotides.
Agnieszka Gorska (482400)   +5 more
core   +1 more source

Long-term administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces kyphosis

open access: yes, 2008
The mdx mouse model of muscular dystrophy has a premature stop codon preventing production of dystrophin. This results in a progressive phenotype causing centronucleation of skeletal muscle fibers, muscle weakness and fibrosis and kyphosis.
Laws, Nicola   +6 more
core   +1 more source

Antisense Oligonucleotides: Potential Therapeutics in Neurology and Beyond

open access: yes, 2021
A brief discussion of Antisense Oligonucleotides and their application to Neurology and COVID-19.
Knepp, Bodie
core   +1 more source

Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: A comparison of tricyclo-DNA with LNA [PDF]

open access: yes, 2004
The nuclear antisense properties of a series of tricyclo(tc)-DNA oligonucleotide 9-15mers, targeted against the 3' and 5' splice sites of exon 4 of cyclophilin A (CyPA) pre-mRNA, were evaluated in HeLa cells and compared with those of corresponding LNA ...
Schümperli, Daniel   +10 more
core   +3 more sources

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis

open access: yesAnnals of Clinical and Translational Neurology
Antisense oligonucleotides, which are used to silence target genes, are gaining attention as a novel drug discovery modality for proteinopathies. However, while clinical trials for neurodegenerative diseases like amyotrophic lateral sclerosis have been ...
Daisuke Ito, Kensuke Okada
doaj   +1 more source

Antisense Oligonucleotides Targeting SARS-CoV-2

open access: yes, 2022
COVID-19 is treated with antisense oligonucleotides (ASOs) targeting SARS-CoV-2 viral RNAs or human ACE2 RNA.
Karstensen, Kasper; id_orcid   +3 more
core  

Home - About - Disclaimer - Privacy